TABLE 3.
Alignment of Synthesized Qualitative and Quantitative Findings Confirming (CONF), Complementing (COMP), or Diverging from (DIV) Each Other
| Qualitative Findings | Quantitative Findings | Qualitative Findings | Quantitative Findings |
|---|---|---|---|
| Favoring Adherence (FES, # reports) | Favoring Adherence (ratio (d), # relationships) | Favoring Nonadherence (FES, # reports) | Favoring Nonadherence (ratio (d), # relationships) |
| Set A | |||
| 1. Belief in effectiveness, advantages, lack of harm of ARVs (42%, k = 5) (CONF #2) | 2. Equivocal about effectiveness, toxicity of ARVs (50%, k =6) (CONF #1) | ||
| Set B | |||
| 3. Supportive, trustworthy, & demonstrably caring provider(38%, k = 5) (CONF #5) | 4. Unsupportive, untrustworthy, inaccessible, or demonstrably uncaring provider (23%, k = 3) (CONF #3) | ||
| Set C | |||
| 5. Having children (desire to live for them; 31%, k = 4) (DIV#6) | 6. Having children (caregiving competes with self-care; (15%, k = 2) (DIV #5) | ||
| Set D | |||
| 7. Family/friends have positive view, are supportive, remind to take (31%, k = 4) (CONF #8) | 8. Family/friends have negative view, not supportive, cause distress (23%, k = 3) (CONF #7) | ||
| Set E | |||
| 9. Having less complex regimen, allows integration into routine schedule (31%, k = 4) (CONF#11, COMP #10, 12) | 10. Less frequent dosing (100%; k = 2) (COMP #9, 11, 12, 13) | 11. Having ARV regimen difficult to execute in routine daily schedule (46%, k = 6) (CONF#9, COMP #10, 12) | |
| 12. Pills hard to take, too many(31%, k = 4) (COMP #9, 10, 11) | |||
| Set F | |||
| 13. Viewing ARVs as symbol of hope and survival, way to live longer (31%, k = 4) (COMP #14, 15) | 14. Optimism (33%, k = 3) (COMP #13) | 15. Viewing ARVs as reminder of HIV/deviant status (23%, k = 3) (COMP #13) | |
| Set G | |||
| 16. Having no symptoms of HIV, feeling healthy (23%, n = 3) (DIV #17, 18, 21; COMP #19) | 18. Opportunistic infections (50%, k = 2) (COMP #17; DIV #16, 21) | 21. Having no symptoms of HIV, feeling healthy or better (38%, k = 5) (DIV #16, 17, 18; COMP#19) | |
| 17. Feeling sick, having symptoms(15%, k = 2) (DIV #16, 19, 21; COMP #18) | 19. Higher CD4 counts (83%, k = 6) (COMP #16, 21; DIV #17, 20) | ||
| 20. Higher detectable viral load(50%, k = 4) (DIV #19) | |||
| Set H | |||
| 22. Having no side effects or manageable side effects of ARV(15%, k = 2) (CONF #23) | 23. Side effects of ARVs (92%, k = 12) (CONF #22) | ||
| Set I | |||
| 24. Knowledge/understanding of HIV and ARVs (15%, k = 2) (COMP #25, 26, 27) | 25. More education (14%, k = 7) (COMP #24) | ||
| 26. Older (20%, k = 5) (COMP #24) | |||
| 27. Taking ARVs > 2 years (50%, k = 2) (COMP #24) | |||
| Set J | |||
| 28. Viewing ARVs as racist, genocidal (African American women; 15%, k = 2) (COMP #29) | 29. Black (vs. white; 50%, k = 2) (COMP #28) | ||
| Set K | |||
| 30. Negative emotions/trauma associated with HIV (38%, k = 5) (CONF #31) | 31. Depression (40%, k = 5) (CONF #30) | ||
NOTE: ARV = antiretroviral; FES = frequency effect size